User:Mark Macbeth/Sandbox8

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
==LSD-1: Human lysine-specific demethylase 1==
+
=''H. sapiens'' Lysine Methyltransferase, SET 7/9=
-
<StructureSection load='2h94' size='330' frame='true' side='right' caption='LSD-1 (PDB: 2H94) overall 3D structure: Tower domain (blue), SWIRM domain (yellow), Oxidase domain (red), and FAD cofactor (green).' scene='81/811090/Overall_lsd-1/1'>
+
-
== Introduction ==
+
<StructureSection load='1O9S' size='350' frame='true' side='right' caption='H. sapiens KMT 1o9s' 'scene=81/811707/Kmt_active_site/1'>
-
[[Image:Histone.png|200 px|right|thumb|Figure 1: DNA (red) wrapped around histone proteins with histone tails (blue)]]
+
-
<scene name='81/811090/Overall_lsd-1/1'>LSD-1</scene>, human lysine-specific demethylase 1, is an enzyme that affects the ability of DNA to associate with [https://en.wikipedia.org/wiki/Histone histone proteins]. Histone proteins are positively charged proteins that act as spools for negatively charged DNA to wrap around for storage as in the nucleus (Figure 1). When DNA is tightly condensed it forms into nucleosomes which consist of 8 histone core proteins (2 H2A, 2 H2B, 2 H3, 2 H4) with DNA tightly coiled around them. This tightly coiled DNA is known as [https://en.wikipedia.org/wiki/Heterochromatin heterochromatin], which is inaccessible to transcription factors and RNA polymerase. This can be reversed by modifications to histone protein structure that cause the DNA to relax and form [https://en.wikipedia.org/wiki/Euchromatin euchromatin], which allows for RNA polymerase and other transcription factors to properly execute transcription. One key histone modification is the [https://en.wikipedia.org/wiki/Demethylase demethylation] of lysine residues. Before 2004, it was believed that methylation of histone tails was stable and irreversible. In 2004, it was discovered that histone tails can also be demethylated by demethylase enzymes such as LSD-1 <ref name="Shi">doi: 10.1016/j.cell.2004.12.012</ref>. LSD-1 specifically demethylates mono- or di-methylated lysine substrates on the histone tail of H3 on Lys4 or Lys9. Demethylation of these lysine residues is commonly associated with transcriptional activation, but it also has the ability to silence genes depending on the residue being demethylated, the cofactors present, and the environment in which the demethylation occurs. LSD-1 is among the most well-known demethylases and has been studied since its instrumental discovery in 2004 <ref name="Shi"/>.
+
-
== Structure ==
+
==Introduction==
-
[[Image:methyl1.gif|left]]
+
-
<scene name='81/813450/Stupidsurface/1'>stupiudsurface</scene>
+
-
=== Tower Domain ===
+
-
[[Image:COREST.png|200 px|left|thumb|Figure 2: CoRest complex (purple) bound to LSD1 at the Tower domain.]]
+
-
The <scene name='81/811088/Towerdomain/2'>tower domain</scene> is a 100 residue protrusion off of the main protein body of LSD-1, comprised of 2 [https://en.wikipedia.org/wiki/Alpha_helix-helices 𝛂-helices]. The longer helix, T𝛂A, is an LSD-1 specific element that has not been found in any other oxidase proteins <ref name="Stavropolous">doi: 10.1038/nsmb1113</ref>. The shorter helix, T𝛂B, is positioned near the active site of the oxidase domain. In fact, T𝛂B connects directly to helix 𝛂D of the oxidase domain through a highly conserved connector loop. The exact function of the tower domain is not known, but it is proposed to regulate the size of the active site chamber through this <scene name='81/811090/Tb-dinteraction/1'>TαB-αD interaction</scene>. The T𝛂B-𝛂D interaction is responsible for the proper positioning of <scene name='81/811090/Phe538-tyr761interaction/1'>Phe538</scene>, a side chain of 𝛂D that is located in the catalytic chamber for proper recognition and binding of the substrate lysine through hydrophobic interactions. In addition, the T𝛂B-𝛂D interaction positions 𝛂D in the correct manner to provide [https://en.wikipedia.org/wiki/Hydrogen_bond hydrogen bonding] to <scene name='81/811090/Phe538-tyr761interaction/1'>Tyr761</scene>. Tyr761 is positioned in the catalytic chamber next to the FAD cofactor and aids in the binding of the lysine substrate <ref name="Stavropolous"/>. Therefore, the base of the tower domain forms a direct connection to the oxidase domain and plays a crucial role in the shape and catalytic activity of the active site. In fact, removing the tower domain via a mutation resulted in a drastic decrease in catalytic efficiency <ref name="Stavropolous"/>. The tower domain has also been found to interact with other proteins and complexes, such as CoREST (Figure 2), as a molecular lever to allosterically regulate the catalytic activity of the active site <ref name="Yang">doi: 10.1016/j.molcel.2006.07.012</ref>. Overall, the exact function of the tower domain has not yet been fully determined, but it is known to be vital to the catalytic activity of LSD-1.
+
 +
[https://en.wikipedia.org/wiki/Histone Histones] are a family of proteins that condense DNA into chromatin, and is an octamer composed of two of each protein core; H2A, H2B, H3, and H4. Histones are a globular protein, that often have N- or C-terminal tails. These tails can often be subjected to modifications by enzymes. Methylation of histones is one of the four common histone modifications. Methylation is most common on long tails of H3 and H4 due to the tail being able to enter the active site.<ref name ="DesJarlais" /> A histone can be mono-, di-, or tri- methylated. Once the histone is methylated, the DNA goes from tightly bound heterochromatin to loosely packed euchromatin. The euchromatin allows RNA pol II to bind to the DNA and start transcription. <ref name="Marino" /> Histone methylation is also a major epigenetic marker, which can be passed down from generation to generation. A epigenetic marker affects the way that genes are expressed, and can either activate or repress DNA. Histone methylation is a major epigenetic marker because it has the ability to change heterochromatin to euchromatin, and vise versa. Alterations in markers have been associated with many diseases.<ref name="Xiao" /> Lysine Methyltrasferase SET7/9 (KMT) is an enzyme that methylates the histone 3 lysine 4 (H3K4) and plays a important role in the transcription of DNA in H. sapiens.<ref name="Biterge" /> It is composed of 259 residues and is a monomer containing a SET domain. There is a two-domain architecture containing a conserved anti-parallel β-barrel and an unusual knot-like structure that creates the active site. It also contains a cofactor that plays a role in the active site.The methylation of H3K4 results in transcriptional activation.<ref name="Biterge" /> The specific methylation of H3K4 does not result in a change in charge because it is a nonpolar group being added to the lysine. A change in charge could result in tighter bound heterochromatin.
-
=== SWIRM Domain ===
 
-
The <scene name='81/811088/Swirmdomain/5'>SWIRM domain</scene> is seen in numerous enzymes that participate in histone binding and chromatin modification. The SWIRM domain of LSD-1 is 94 residues long and is comprised of an alpha-helix bundle <ref name="Stavropolous"/>. The longest helix, 𝛂C, separates the two other helix-turn-helix motifs, <scene name='81/811088/Swirmmotifs/4'>𝛂A/B and 𝛂D/E </scene><ref name="Stavropolous"/>. The SWIRM domain is associated with the oxidase domain via hydrophobic [https://en.wikipedia.org/wiki/Van_der_Waals_force van der Waals interactions] between <scene name='81/811088/Oxidaseandswirmchillin/4'>3 𝛂-helices in each domain</scene>: 𝛂A, 𝛂B, and 𝛂E motifs in the SWIRM domain and 𝛂A, 𝛂B, 𝛂M, motifs in the oxidase domain. The residues that create this hydrophobic interface (which spans nearly 1680 Ų) are practically invariant across histone-modifying proteins <ref name="Stavropolous"/>. The <scene name='81/811090/Hydrophobic_interface_new/1'> hydrophobic interface between the oxidase and SWIRM domains</scene> creates a cleft or tunnel that is also present in other chromatin modifying enzymes. This <scene name='81/811090/Hydrophobic_interface_new/3'>cleft</scene> is responsible for binding to DNA in the other enzymes through the presence of positively charged residues in the cleft <ref name="Stavropolous"/>. The SWIRM domain in LSD-1 is unique because the cleft that is formed by the hydrophobic SWIRM-oxidase interactions lacks the positively charged residues common in other enzymes <ref name="Stavropolous"/>. For this reason, it is proposed that the SWIRM cleft is used for binding of a histone tail (on the same histone as the substrate lysine) in order to hold the histone in place. Multiple experiments showed that mutations in hydrophobic residues that form the SWIRM-oxidase interface greatly reduced the catalytic activity of LSD-1 <ref name="Stavropolous"/>. This, and the proximity to the active site in the oxidase domain, exhibit the importance of the SWIRM cleft in the mechanism of LSD-1.
 
-
=== Oxidase Domain ===
+
==Structure==
-
The <scene name='81/811088/Oxidasedomain/3'>oxidase domain</scene> is responsible for housing the site of catalytic activity in LSD-1. The domain has two distinct subunits: one non-covalently binds the FAD cofactor and the other acts in both the binding and recognition of the substrate lysine on a histone tail(H3)<ref name="Stavropolous"/>. The active site cavity is placed within the substrate-binding subunit of the oxidase domain and is unique due to its great size. In relation to other FAD-dependent oxidases, LSD-1 has an immense active site cavity that is 15 Å deep and 25 Å at its widest opening <ref name="Stavropolous"/>. In comparison, [https://en.wikipedia.org/wiki/Polyamine_oxidase polyamine oxidase], another FAD-dependent oxidase, has a catalytic chamber roughly 30 Å long but only a few angstroms wide <ref name=”Binda”>PMID:11258887</ref>. The relatively large size of the LSD-1 active site cavity suggests that other residues, in addition to the substrate lysine, enter into the active site during catalysis. These additional residues could participate in substrate recognition and may contribute to the enzyme’s specificity for H3K4 and H3K9.
+
-
====Active Site and FAD Cofactor====
+
===SET Domain===
-
Within the active site cavity, there are four invaginations, or <scene name='81/811090/Active_site_pockets/1'>active site pockets</scene>, each with differing chemical properties. The catalytic pocket or invagination within the active site (residues Val317, Gly330, Ala331, Met332, Val333, Phe538, Leu659, Asn660, Lys661, Trp695, Ser749, Ser760 and Tyr761) catalyzes the interaction between the FAD cofactor and the substrate lysine <ref name="Stavropolous"/>. This pocket binds and positions the substrate lysine so that it is exposed to the <scene name='81/811089/Fadcofactor/4'>FAD cofactor</scene>. During catalysis, the FAD cofactor is reduced and becomes an anion. Therefore, a positively charged residue is present in most FAD-dependent oxidases to assist in stabilizing the anionic form of FAD. In LSD-1, <scene name='81/811088/Lys661/3'>Lys661</scene> is present in the catalytic pocket of the active site to stabilize the negatively charged FAD <ref name="Stavropolous"/>. The other three <scene name='81/811090/Active_site_pockets/1'>pockets</scene> are not as well understood but predictions can be made about their functions within the active site of LSD-1. Because the active site is able to accept additional residues on the substrate histone other than the lysine, the remaining three pockets are most plausibly responsible for the recognition of chemical modifications on the histone itself <ref name="Stavropolous"/>. The first pocket (Pocket 1) that assists in recognizing chemical modifications on the substrate histone is composed of residues Val334, Thr335, Asn340, Met342, Tyr571, Thr810, Val811 and His812 <ref name="Stavropolous"/>. The second pocket in the active site for side-chain recognition (Pocket 2) is composed of Phe558, Glu559, Phe560, Asn806, Tyr807 and Pro808 <ref name="Stavropolous"/>. Pocket 3 within the active site is composed of Asn540, Leu547, Trp552, Asp553, Gln554, Asp555, Asp556, Ser762, Tyr763, Val764 and Tyr773 <ref name="Stavropolous"/>. Each of the three pockets, in addition to the catalytic pocket, are able to recognize distinct modifications on the substrate and contribute to the specificity of LSD-1.
+
 +
The <scene name='81/811707/Overall_structure/1'>human lysine methyltransferase </scene>(HKMT) SET7/9 is 366 amino acids long. The overall structure looks like a dimer although it acts as a monomer. The structure is composed of the ΔSET7/9 domain. The ΔSET7/9 consists of the SET domain along with the pre- and post-SET regions.<ref name="Schubert" /><ref name="Yeates" /> The pre- and post-SET regions are adjacent to SET domain and are cysteine rich.<ref name="Schubert" /><ref name="Yeates" /> The pre-SET cysteine region is located near the N-terminal where the post-SET region is located near the C-terminal of the domain.<ref name="Schubert" /><ref name="Yeates" /> These regions are said to play an important role in substrate recognition and enzymatic activity.<ref name="Schubert" /><ref name="Yeates" />
-
== Mechanism of Action==
+
The SET domain is mostly defined by <scene name='81/811707/Variable_knot/2'>turns and loops</scene> with the few <scene name='81/811707/Beta_sheets/3'>antiparallel β-sheets</scene>.<ref name="Schubert" /> <scene name='81/811707/Beta-hairpin/3'>Residues 337-349</scene> form a β-hairpin that sticks out at a right angle to the surface of the enzyme.<ref name="Xiao" /> The following three residues (<scene name='81/811707/Sharp_bend/3'>350-352</scene>) accommodate a sharp bend in the peptide chain and the end of the protein adopts an <scene name='81/811707/C-term_alpha_helix/2'>α-helical conformation</scene>.<ref name="Xiao" /> The two most defining features of the SET domain are the C-terminal tyrosine and the knot-like fold. These two components have been recognized to be essential for <scene name='81/811707/Sam_isolated/2'>S-adenosyl-L-methionine</scene> (SAM) binding and catalysis.<ref name="Schubert" /> <ref name="Yeates" /> <ref name="Huang" /> The knot-like fold contains the binding sites for the cofactor SAM and the peptide substrate.<ref name="Licciardello" />
-
[[Image:LSD1Mechanism.png|700 px|right|thumb|Figure 3: Hydride transfer mechanism of LSD-1 active site via FAD cofactor.]]
+
-
The mechanism of lysine demethylation is highly dependent on the presence of the <scene name='81/811089/Fadcofactor/4'>FAD cofactor</scene>. The FAD cofactor, positioned closely to the substrate lysine in the active site, acts as an oxidizing agent and initiates catalysis (Figure 3). A two-electron transfer occurs between the substrate lysine and FAD in the form of a [https://en.wikipedia.org/wiki/Hydride hydride]; the lysine is oxidized and the FAD is reduced <ref name="Stavropolous"/>. The FAD cofactor forms an anion and is stabilized by the positively charged <scene name='81/811088/Lys661/3'>Lys661</scene> positioned in the catalytic pocket of the active site <ref name="Stavropolous"/>. The oxidized lysine forms an aminium cation that is hydrolyzed into the carbinolamine intermediate <ref name="Stavropolous"/>. The carbinolamine intermediate readily decomposes into formaldehyde and the demethylated lysine substrate <ref name="Stavropolous"/>.
+
[[Image:KMT_Channel.png|300 px|right|thumb|Figure 1: Narrow Lysine Channel]]
 +
===Active Site and Channel===
-
===Inhibition by Tri-Methylated Lysine===
 
-
[[Image:Tri-methylated Lysine.png|90 px|right|thumb|Figure 4: Tri-methylated lysine.]]
 
-
The proposed LSD-1 mechanism is supported by the fact that tri-methylated lysine substrates (Figure 4) competitively inhibit the enzyme. A substrate lysine that is tri-methylated binds to the active site but does not undergo catalysis; the inhibition is not steric (the active site is large enough to accommodate tri-methylated lysines), but is rather chemical in nature. Tri-methylated lysines do not have a free lone pair to form an aminium cation as is necessitated by the proposed mechanism, resulting in chemical inhibition of LSD-1 <ref name="Stavropolous"/>. Thus, the mechanism of LSD-1 contributes to its specificity for mono- or di-methylated lysine substrates (Figure 4).
 
-
== Medical Implications ==
+
The most notable feature of the HKMT is the presence of the lysine access channel as the active site. The cofactor and <scene name='81/811708/Sam_structure/3'>peptide</scene> substrate are actually located on opposite sides of the SET domain but are connected through this narrow channel (Figure 1).<ref name="Xiao" /> This channel allows these two components to interact and complete the methyltransfer. The active site in general is considerably tyrosine rich. Residues Tyr245, His297, Ser268, Tyr305, Tyr335, and Tyr337 all help to shape the <scene name='81/811707/Stick_active_site/2'>active site</scene> and the channel.<ref name="Xiao" /> The cofactor involved, SAM, provides the methyl for methylation of the lysine on its sulfur atom.
-
Knowledge about LSD-1 in the scientific community remains fairly rudimentary as it was discovered recently in 2004 <ref name="Shi"/>. However, the physiological implications that LSD-1 may have on medical conditions are being researched. LSD-1 has proposed roles in both diabetes and in cancer development.
+
-
===1. Diabetes===
+
[[Image:Water.PNG|300 px|right|thumb|Figure 2: Water being utilized in the active site]]
-
[https://en.wikipedia.org/wiki/Gluconeogenesis Gluconeogenesis] is a process in the body that results in the production of glucose from non-carbohydrate forms (such as lactic acid). G6Pase and FBP1 are critical enzymes in the gluconeogenesis pathway. LSD-1, although it can have both activating and inhibiting effects depending on external conditions, is proposed to have inhibiting effects on the transcription of both G6Pase and FBP1 <ref name="Dongning">doi: 10.1371/journal.pone.0066294</ref>. Under healthy conditions, LSD-1 inhibits the transcription of these enzymes in order to regulate the blood glucose levels in the body. It was found that decreased amounts of LSD-1 in the body can induce [https://en.wikipedia.org/wiki/Hyperglycemia hyperglycemia] that contributes to the formation of both types of diabetes <ref name="Dongning"/>.
+
-
===2. Cancer===
+
The beta hairpin stabilizes the <scene name='81/811707/Beta_hairpin_stabilizing_tyrs/1'>conformation of Tyr335 and Tyr337</scene>, while also shaping one side of the channel which the peptide binds to.<ref name="Xiao" /> The <scene name='81/811707/Peptide_binding_site/1'>peptide binding groove</scene> is composed of residues 255-268.<ref name="Xiao" /> Lysine would have trouble coming down into the active site in its charged form, but it is facilitated by the faces of the flanking tyrosines.<ref name="Xiao" /> The orientation of the lysine is such that the amine-methyl bond is aligned towards the sulfur on SAM so that it can provide the methyl. There is an important water in the active site (Figure 2) as well that acts as a stabilizer for lysine, and helps to shift the lone pair on the nitrogen towards the sulfur of SAM. <ref name="Xiao" />
-
Research has found that LSD-1 is over-expressed in many tumorous cancers. The proposed mechanism behind the carcinogenic role of LSD-1 focuses on the known tumor-suppressor gene, [https://en.wikipedia.org/wiki/P53 p53]. The p53 protein acts as a transcription factor that activates the expression of many anti-proliferative proteins. LSD-1 has been found to remove a methyl group from the di-methylated Lys370 on p53 <ref name="Jin">PMID:23072722</ref>. Similar to the proposed role of LSD-1 in diabetes, its demethylation of p53 is inhibitory and prevents its binding to DNA <ref name="Jin"/>. This inactivation of p53 is thought to prevent anti-proliferative operations in the cell and contribute to the development of multiple types of cancers.
+
 +
 +
== Function ==
 +
 +
[[Image:KMT Mechanism .png|500 px|right|thumb|Figure 3: Histone Methylation by HKMT Mechanism]]
 +
 +
The N from the lysine serves as a nucleophile that attacks the electrophilic CH<sub>3</sub> that is present in the AdoMet. The sulfur that the CH<sub>3</sub> is attached to pulls the electrons towards itself to weaken the bond between the sulfur and the carbon. This weak bond allows for the N to break that bond and take the methyl group. The N on the lysine is being stabilized by Tyr residues and a water molecule (Figure 3). This allows the N to gain the methyl and take up that positive charge.
 +
 +
The conserved regions of KMT has been found to be vital for function. Multiple studies have found that a mutation to any of the conserved tyrosine residues continues to monomethylate SAM, while it also creates di-methylation and tri- methylation of SAM.<ref name="Del Rizzo" /> In a recent study, Y245A and Y305F were created through site-directed mutagenesis.<ref name="Del Rizzo" /> Due to size, Ala245 was found to create a larger opening of the channel than tyrosine, which allowed for further methylation of SAM. <ref name="Del Rizzo" /> However, Y305F also showed the same characteristics of di- and tri-methylation, most likely due to a decrease of tyrosine residue interaction with water.<ref name="Del Rizzo" /> As there are four invariant conserved tyrosine residues (Tyr305, Tyr245, Tyr335, Tyr337) in the active site, this finding indicates that the function of KMT is dependent on the presence of tyrosine residues in the active site. <ref name="Del Rizzo" />
 +
 +
== Relevance ==
 +
 +
===Renal Fibrosis===
 +
[[Image:Sam_vs_sinefungin.png|400 px|right|thumb|Figure 4: Structural differences between SAM and Sinefungin]]
 +
The inhibition of KMT SET 7/9 has been found to enhance renal fibrosis.<ref name="Sun" /> H3K4 methylation activates the transcription of fibrotic genes, and the suppression of the H3K4 methylation was found to enhance renal fibrosis in a mouse model.<ref name="Sun" /> Sinefungin, a competitive methyltransferase inhibitor, binds to KMT to inhibit SAM.<ref name="Sun" /> SAM and Sinefungin have similar structures (Figure 4), differing only with the removal of a sulfide and the replacement of a methyl to an amine. The amine replaces the methyl donor for the reaction of KMT, inhibiting the reaction and preventing methylation. Without the methylation of H3K4, the transcription of fibrotic genes is deactivated, leading to renal fibrosis.<ref name="Sun" />
 +
 +
===Cancer===
 +
 +
Many studies have shown that lysine methyltransferases lead to the inhibition of cancers, therefore they are being studied as possible cancer therapy treatments. Lysine methylation contributes to the inactivation of a tumor suppressor gene. Due to this, KMTs are being studied as possible biomarkers for the detection of cancers. Inhibitors of KMT, such as Sinefungin (Figure 4), were used in a study to observe KMT’s effect on cancerous cells. It was found that when KMT is deregulated, tumor behavior increases due to a lack of methylation, indicating the importance of the histone methylation. <ref name=Xuejiao />
 +
 +
</StructureSection>
== References ==
== References ==
 +
<ref name="Xiao">PMID: 12540855 </ref>
 +
<ref name ="Licciardello" <ref>DOI: 10.1016/C2014-0-02189-2</ref>
 +
<ref name="Schubert">PMID: 12826405 </ref>
 +
<ref name="Yeates">PMID: 12372294 </ref>
 +
<ref name="Huang">PMID: 9632640 </ref>
 +
<ref name="Del Rizzo">PMID: 20675860 </ref>
 +
<ref name="Sun">PMID: 20930066 </ref>
 +
<ref name="Xuejiao" <ref> DOI: 10.2174/1568009611313050007 </ref>
 +
<ref name="DesJarlais" <ref> DOI: 10.1021/acs.biochem.5b01210 </ref>
 +
<ref name="Marino">PMID: 16209651 </ref>
 +
<ref name="Biterge" <ref> DOI: 10.15406/mojcsr.2016.03.00047</ref>
<references/>
<references/>
-
</StructureSection>
+
==Student Contributors==
 +
Ashley Crotteau
 +
 +
Parker Hiday
-
== Student Contributors ==
+
Lauren Allman
-
*Nicholas Bantz
+
-
*Cody Carley
+
-
*Michael Thomas
+

Revision as of 13:24, 16 April 2019

H. sapiens Lysine Methyltransferase, SET 7/9

H. sapiens KMT 1o9s

Drag the structure with the mouse to rotate

References

[3] [8] [5] [6] [7] [9] [10] [11] [1] [2] [4]

  1. 1.0 1.1 DesJarlais R, Tummino PJ. Role of Histone-Modifying Enzymes and Their Complexes in Regulation of Chromatin Biology. Biochemistry. 2016 Mar 22;55(11):1584-99. doi: 10.1021/acs.biochem.5b01210. Epub , 2016 Jan 26. PMID:26745824 doi:http://dx.doi.org/10.1021/acs.biochem.5b01210
  2. 2.0 2.1 Marino-Ramirez L, Kann MG, Shoemaker BA, Landsman D. Histone structure and nucleosome stability. Expert Rev Proteomics. 2005 Oct;2(5):719-29. PMID:16209651 doi:http://dx.doi.org/10.1586/14789450.2.5.719
  3. 3.0 3.1 3.2 3.3 3.4 3.5 3.6 3.7 3.8 3.9 Xiao B, Jing C, Wilson JR, Walker PA, Vasisht N, Kelly G, Howell S, Taylor IA, Blackburn GM, Gamblin SJ. Structure and catalytic mechanism of the human histone methyltransferase SET7/9. Nature. 2003 Feb 6;421(6923):652-6. Epub 2003 Jan 22. PMID:12540855 doi:10.1038/nature01378
  4. 4.0 4.1 4.2 doi: https://dx.doi.org/10.15406/mojcsr.2016.03.00047
  5. 5.0 5.1 5.2 5.3 5.4 5.5 5.6 Schubert HL, Blumenthal RM, Cheng X. Many paths to methyltransfer: a chronicle of convergence. Trends Biochem Sci. 2003 Jun;28(6):329-35. PMID:12826405
  6. 6.0 6.1 6.2 6.3 6.4 6.5 Yeates TO. Structures of SET domain proteins: protein lysine methyltransferases make their mark. Cell. 2002 Oct 4;111(1):5-7. PMID:12372294
  7. 7.0 7.1 Huang S, Shao G, Liu L. The PR domain of the Rb-binding zinc finger protein RIZ1 is a protein binding interface and is related to the SET domain functioning in chromatin-mediated gene expression. J Biol Chem. 1998 Jun 26;273(26):15933-9. PMID:9632640
  8. 8.0 8.1 doi: https://dx.doi.org/10.1016/C2014-0-02189-2
  9. 9.0 9.1 9.2 9.3 9.4 9.5 Del Rizzo PA, Couture JF, Dirk LM, Strunk BS, Roiko MS, Brunzelle JS, Houtz RL, Trievel RC. SET7/9 catalytic mutants reveal the role of active site water molecules in lysine multiple methylation. J Biol Chem. 2010 Oct 8;285(41):31849-58. Epub 2010 Aug 1. PMID:20675860 doi:http://dx.doi.org/10.1074/jbc.M110.114587
  10. 10.0 10.1 10.2 10.3 10.4 Sun G, Reddy MA, Yuan H, Lanting L, Kato M, Natarajan R. Epigenetic histone methylation modulates fibrotic gene expression. J Am Soc Nephrol. 2010 Dec;21(12):2069-80. doi: 10.1681/ASN.2010060633. Epub 2010, Oct 7. PMID:20930066 doi:http://dx.doi.org/10.1681/ASN.2010060633
  11. 11.0 11.1 Tian X, Zhang S, Liu HM, Zhang YB, Blair CA, Mercola D, Sassone-Corsi P, Zi X. Histone lysine-specific methyltransferases and demethylases in carcinogenesis: new targets for cancer therapy and prevention. Curr Cancer Drug Targets. 2013 Jun;13(5):558-79. doi:, 10.2174/1568009611313050007. PMID:23713993 doi:http://dx.doi.org/10.2174/1568009611313050007

Student Contributors

Ashley Crotteau

Parker Hiday

Lauren Allman

Proteopedia Page Contributors and Editors (what is this?)

Mark Macbeth

Personal tools